Résumé
Objective: To determine the course and efficacy of peritoneal dialysis in children presenting with renal failure
Study Design: Quasi experimental study
Place and Duration of Study: The study was conducted at the Nephrology department of Children's Hospital and Institute of Child Health Lahore from Feb 2007 to Feb 2008
Material and Methods: Forty children diagnosed with renal failure at the Nephrology department of Children's Hospital and Institute of Child Health, Lahore were evaluated for the efficacy of PD, duration of PD and the associated complications
Results: There were 55% cases of acute renal failure and 45% cases of chronic renal failure. The mean duration of PD was 3.8 days. About 75% of all the patients improved with PD. The mortality rate was 22.5%. Leading complications were Catheter-related [leakage/blockade] and peritonitis
Conclusion: We concluded that peritoneal dialysis is lifesaving procedure which improves the acute metabolic derangements of renal failure in children. It is associated with certain complications but the benefits outweigh the complications
Résumé
To determine the in vitro efficacy of tigecycline against methicillin resistant Staphylococcus aureus [MRSA]. Department of Microbiology Army Medical College and Armed Forces Institute of Pathology Rawalpindi, from Feb 2008 to Jan 2009. One hundred clinical isolates of MRSA were taken, Detection of MRSA was done using 30 microg disc of cefoxitin as recommended by Clinical laboratory Standard Institute [CLSI]. Susceptibility of the isolates to tigecycline was done by employing modified Kirby Bauer disk diffusion technique, according to the guidelines provided by the Food and Durg Administration [FDA]. Minimum inhibitory concentrations [MICs] of the isolates were determined by using E-strips [bioMerieux] of tigecycline. Results were interpreted according to FDA recommendations. All MRSA isolates were susceptible to tigecycline by disc diffusion method. The MICs of tigecycline revealed that all MRSA isolates were in sensitive range. In an era of rapidly growing antibiotic resistance, tigecycline has been found to have very good in vitro efficacy against MRSA isolates